Therapies in ankylosing spondylitis—from clinical trials to clinical practice
Author:
Open Access
- 1 November 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (suppl_6) , vi23-vi28
Abstract
Until recently, the therapeutic options for patients suffering from active AS comprised NSAIDs and TNF inhibitor therapy. Although these are effective in a significant proportion of patients, not all patients respond and some are intolerant to these therapies. Therefore, there is a clear unmet treatment need in AS patients. This article reviews the evidence for targets currently being studied in AS. This includes the IL-12/23 inhibitor ustekinumab, the pan-Janus kinase inhibitor tofacitinib and the anti-IL-17A antibody secukinumab.Keywords
Funding Information
- Novartis and Pfizer
- Novartis
- AbbVie and Janssen
This publication has 39 references indexed in Scilit:
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2013
- In Situ Analysis of Interleukin–23– and Interleukin‐12–Positive Cells in the Spine of Patients With Ankylosing SpondylitisArthritis & Rheumatism, 2013
- Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE studyAnnals of the Rheumatic Diseases, 2012
- Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot studyAnnals of the Rheumatic Diseases, 2011
- The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in HumansPLOS ONE, 2011
- Different response to rituximab in tumor necrosis factor blocker–naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty‐four–week clinical trialArthritis & Rheumatism, 2010
- Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility lociNature Genetics, 2010
- Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritisArthritis & Rheumatism, 2009
- Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trialArthritis & Rheumatism, 2008
- Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis & Rheumatism, 2008